ABVX abivax.com: רווח נקי למניה ב-12 החודשים האחרונים

Critical risks of failed final drug trials and revenue deficits serve as the primary drivers for ABIVAX (ABVX). This chart of net income per share YoY ttm visualizes these fluctuations, where -101.70 reflects the latest value of the metric. Development relies on partnerships with scientific centers, yet the success of the entire ecosystem depends entirely on FDA and EMA verdicts.
ABIVAX - פילוחים אנליטיים ומדדי מפתח (ABVX)

This indicator measures the annual change in earnings per share over the last 12 months, allowing for an assessment of the growth or decline rates of the business's actual profitability. By analyzing the YoY ttm net income per share chart, an investor can identify valuation overheating, which is critical for ABIVAX (ABVX), whose model is based on capital burn without the presence of commercial products.